| Zeit | Aktuelle Nachrichten Sprache: 
Alle DE EN  | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Genflow Biosciences PLC Announces Total Voting Rights | 145 | ACCESS Newswire | LONDON, UK / ACCESS Newswire / October 31, 2025 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company"), an emerging leader in the field of longevity research, focused on developing... ► Artikel lesen  | |
| Fr | Genflow Biosciences - Total Voting Rights | 2 | RNS | ||
| GENFLOW BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 24.10. | Genflow Biosciences PLC Announces Holding(s) in Company | 145 | ACCESS Newswire | LONDON, UK / ACCESS Newswire / October 24, 2025 / TR-1: Standard form for notification of major holdings1. Issuer DetailsISINGB00BP2C3V08Issuer NameGENFLOW BIOSCIENCES PLCUK or Non-UK IssuerUK2. Reason... ► Artikel lesen  | |
| 22.10. | TRADING UPDATES: Genflow patent progress; Accsys new debt facilities | 1 | Alliance News | ||
| 22.10. | Genflow Biosciences announces second European patent application | 2 | Seeking Alpha | ||
| 22.10. | Genflow Biosciences PLC Announces Second European Patent Application | 169 | ACCESS Newswire | THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK... ► Artikel lesen  | |
| 22.10. | Genflow Biosciences - Second European Patent Application | 2 | RNS | ||
| 20.10. | Genflow Biosciences says European patent publication is "step forward" | 2 | Alliance News | ||
| 20.10. | Genflow Biosciences PLC Announces Recognition of Patentability of Claims | 137 | ACCESS Newswire | THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK... ► Artikel lesen  | |
| 20.10. | Genflow Biosciences - Recognition of Patentability of Claims | 2 | RNS | ||
| 10.10. | Genflow Biosciences hails data from trial of dog ageing gene therapy | 1 | Alliance News | ||
| 10.10. | Genflow Biosciences PLC Announces Update on Animal Health Program | 168 | ACCESS Newswire | THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK... ► Artikel lesen  | |
| 10.10. | Genflow Biosciences - Update on Animal Health Program | 1 | RNS | ||
| 09.10. | Genflow Biosciences PLC Announces Update, Equity Issue and PDMR Notification | 181 | ACCESS Newswire | THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK... ► Artikel lesen  | |
| 09.10. | Genflow Biosciences - Update, Equity Issue and PDMR Notification | 1 | RNS | ||
| 02.10. | Genflow Biosciences PLC Announces Issue of Equity | 296 | ACCESS Newswire | THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK... ► Artikel lesen  | |
| 02.10. | Genflow Biosciences - Issue of Equity - Correction | 2 | RNS | ||
| 02.10. | SMALL-CAP WINNERS & LOSERS: Argo Blockchain up; Genflow issues shares | 24 | Alliance News | ||
| 02.10. | Genflow Biosciences - Issue of Equity | 2 | RNS | ||
| 30.09. | Genflow Biosciences PLC Announces Half-Year Report | 387 | ACCESS Newswire | LONDON, UNITED KINGDOM / ACCESS Newswire / September 30, 2025 / Genflow (LSE:GENF)(OTCQB:GENFF) is pleased to announce its half year results for the six-month period ended 30 June 2025.Chairman's StatementIt... ► Artikel lesen  | 
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| AVIDITY BIOSCIENCES | 69,82 | +0,04 % | Here's Why Avidity Biosciences Stock Soared This Week (There's More to the Deal Than You Might Think) | ||
| QIAGEN | 39,660 | +0,49 % | Dax lässt nach - Merck und Qiagen gefragt | Frankfurt/Main - Zum Wochenausklang hat der Dax nachgelassen. Zum Xetra-Handelsschluss wurde der Index mit 23.958 Punkten berechnet, ein Minus in Höhe von 0,7 Prozent im Vergleich zum Vortagesschluss.... ► Artikel lesen  | |
| EVOTEC | 7,129 | +1,76 % | Besser als BioNTec, Evotec und Co.? BioNxt Solutions steht vor Meilensteinen und prüft KI-Übernahme - Aktie im Aufwärtstrend | Eine spannende Alternative zu Evotec, BioNTech und Co. ist BioNxt Solutions. Das kanadisch-deutsche Unternehmen unterscheidet sich mit seinem Geschäftsmodell erfrischend von dem klassischer Biotechs... ► Artikel lesen  | |
| BIONTECH | 91,00 | +0,83 % | Innovation trifft Biotech: Dieses Unternehmen mischt Big Pharma mit smarter Wirkstoff-Revolution auf! | Anzeige / WerbungEine spannende Alternative zu Evotec, BioNTech und Co. ist BioNxt Solutions.
Das kanadisch-deutsche Unternehmen unterscheidet sich mit seinem Geschäftsmodell erfrischend... ► Artikel lesen  | |
| MODERNA | 21,755 | -0,78 % | Moderna: Neues zur Tumor-Therapie mRNA-2808 | Moderna hat den ersten Patient in einer klinischen Phase-1/2-Studie mit dem Wirkstoffkandidaten mRNA-2808 behandelt. Der mRNA-basierte T-Cell-Engager wird nach Angaben des US-Biotechunternehmens vom... ► Artikel lesen  | |
| NUVALENT | 93,02 | 0,00 % | Nuvalent, Inc.: Nuvalent Highlights Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Third Quarter 2025 Financial Results | Completed rolling NDA submission for zidesamtinib in TKI pre-treated advanced ROS1-positive NSCLC 
 On track to report topline pivotal data for neladalkib in TKI... ► Artikel lesen  | |
| ARCELLX | 86,02 | 0,00 % | Arcellx: Canaccord Genuity hebt Kursziel wegen höherer Umsatzerwartungen für Anito-Cel an | ||
| TARSUS PHARMACEUTICALS | 69,83 | 0,00 % | Tarsus Pharmaceuticals, Inc: Tarsus to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025 | ||
| BB BIOTECH | 43,950 | +0,57 % | BB Biotech im Aufwind - Zinswende treibt Biotech-Rally an | US-Zinssenkung belebt den Biotech-Sektor. BB Biotech glänzt mit starkem Quartal, vier Exits und klarer Outperformance gegenüber dem Nasdaq Biotech Index. Seit der ersten Zinssenkung der US-Notenbank... ► Artikel lesen  | |
| CUREVAC | 4,586 | -0,86 % | BionTech Aktie startet Übernahme von CureVac - Jetzt Aktien kaufen? | ||
| SPRUCE BIOSCIENCES | 105,01 | 0,00 % | Spruce Biosciences - SPRB: Citizens stuft auf "Market Outperform" hoch! | Einlizenzierung von TA-ERT! Bis zu 170 Mio. Umsatz p.a.! Spruce Biosciences (SPRB) will Zulassungsantrag im I. Quartal 2026 einreichen.  Spruce Biosciences (SPRB) - ISIN US85209E2081 Rückblick: Knaller-Setup... ► Artikel lesen  | |
| MAZE THERAPEUTICS | 33,270 | 0,00 % | Maze Therapeutics, Inc.: Maze Therapeutics Appoints Industry Veteran Hervé Hoppenot as Chairman of the Board of Directors | SOUTH SAN FRANCISCO, Calif., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for... ► Artikel lesen  | |
| SAREPTA THERAPEUTICS | 15,140 | -28,69 % | Baird lowers Sarepta Therapeutics stock price target to $15 on ESSENCE trial failure | ||
| RECURSION PHARMACEUTICALS | 5,260 | -3,13 % | Recursion Pharmaceuticals to Report Q3 Earnings: What's in the Cards? | ||
| STRYKER | 311,80 | +0,26 % | Stryker Corp. Q3 Profit Increases, Beats Estimates | WASHINGTON (dpa-AFX) - Stryker Corp. (SYK) revealed earnings for its third quarter that Increased from the same period last year and beat the Street estimates.The company's earnings came in... ► Artikel lesen  |